Pfizer Terminates DMD Gene Therapy Development, Cuts 210 Jobs

Recently, Pfizer, the world-famous pharmaceutical giant, announced a remarkable decision to officially terminate the development process of its gene therapy Fordadistrogene movaparvovec (PF-06939926) for Duchenne muscular dystrophy (DMD). Behind this decision, it is the drug candidates in the crucial phase III clinical trials CIFFREO failed to reach the preset in the primary efficacy end point, it is to hope and patient population and the DMD treatment had cast a thick layer of shadow.

Pfizer's decision, not only mark the billions of dollars of research and development spending did not translate into the desired treatment breakthrough, more profoundly reveals the drugs for rare diseases difficulties and obstacles on the road. DMD, as a severe hereditary muscle degenerative disease, mainly affects boys. Its course is cruel and the prognosis is poor, which is distressing. Usually starts at the age of 3 to 5 patients with symptoms of muscle weakness, as time goes on, they gradually lose their ability to walk, until the heart and well function is impaired, eventually face the fate of a premature death. Currently, only one gene therapy, Elandistrogene moxeparvovec, has been approved worldwide for the treatment of 4 - to 5-year-old children with DMD who are not in bed, which is both scarce and important.

Pfizer the setbacks, has the sense of urgency and challenging in the field of DMD treatment. Pfizer also plans to cut a total of 210 jobs at two key manufacturing sites in North Carolina in response to rising cost pressures and market competition. Although a company spokesman stressed that the two manufacturing sites "will definitely remain open," the move has sparked widespread concern and discussion inside and outside the industry about the future direction of the pharmaceutical industry.

If we deeply analyze the reasons for the failure of Pfizer's gene therapy, it is not difficult to find that the research and development of rare disease drugs faces many difficult obstacles. First, DMD patients and other rare diseases groups are relatively small, the market demand is limited, this directly led to the drug research and development of high investment and low return risk. Secondly, rare disease pathological mechanism is complicated, often involving multiple genes and signaling pathway of anomaly, the precise design and effective treatment for drugs has brought great challenges. In addition, ethical considerations recruitment difficulty of clinical trials, and regulatory approval of rigor, further increased the difficulty of the drugs for rare diseases and uncertainty.

However, in the face of these challenges and difficulties, we should not give up the exploration and efforts for the treatment of rare diseases such as DMD. Instead, we should take this opportunity to further increase investment and support for rare disease research, promote cutting-edge technology such as gene therapy and cell therapy in the application and progress in the field of DMD. At the same time, we also need to strengthen international cooperation and exchanges, and jointly build a global rare disease research network and resource sharing platform, to speed up the process of developing and promoting new treatments.

We look forward to seeing more pharmaceutical companies and scientific research institutions work together to overcome difficulties and bring more effective and safe treatment options for patients with rare diseases such as DMD. We believe in the near future with the progress of science and technology and innovation to promote the dmo therapeutic areas will usher in a brighter future.